ATP Ventures Partner

What ATP Ventures Partner does

ATP Ventures Partner is a privately held biotech venture creation firm headquartered at 65 Maple Street, Jersey City, New Jersey, founded in 2021 and operating with 11–50 employees. The firm scouts global therapeutic assets and co-founds drug development companies with entrepreneurs and scientists, targeting six therapeutic verticals: anti-aging/longevity, women's health, mental health and psychiatric disorders, metabolism/cardiovascular, ophthalmology, and AI-powered biotech. Its core proposition is hands-on company creation spanning early-stage research through clinical development and market entry, delivered alongside academic partners including Cornell, NYU, Harvard, and UPenn. Managing Partner Drew Zhu leads the firm, and the disclosed portfolio includes Flatbird Therapeutics (women's health, launched March 2024).

On October 8, 2024, ATP acquired Tupelo Brittany, a biotech consulting firm providing fundraising support, business development, in-out licensing, deal-making, market insight, business intelligence, and market development services. The acquisition marks a strategic shift from pure venture capital toward an integrated platform that combines capital with operating and advisory capabilities, with the combined entity operating under the ATP Ventures Partner brand. The firm's revenue model is venture-capital-return driven — equity ownership in co-founded ventures targeting exits via IPOs and M&As — supplemented post-acquisition by consulting services revenue from Tupelo Brittany. ATP's go-to-market is sales-led and direct, with global asset sourcing via the firm's website, press releases, LinkedIn, and outreach to research institutions, and it does not disclose fund size, AUM, management fees, or portfolio concentration metrics.

Name

ATP Ventures Partner

Legal name

ATP Ventures Partner

Website

https://atpvent.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

ATP Ventures Partner is a private biotech venture creation firm, founded in 2021 and based in Jersey City, NJ, that co-founds drug development companies with entrepreneurs and academic partners (Cornell, NYU, Harvard, UPenn). It targets six therapeutic verticals including women's health, longevity, and AI-powered biotech, with Flatbird Therapeutics in its portfolio.

Ownership category

akta.pro rank

Product category

Biotech Venture Capital

NAICS

Management, Scientific, and Technical Consulting Services (5416)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Accelerators & Incubators (Investor-Operated) (FSANAAAM)

Keywords

• Biotech venture capital
• Venture creation services
• Drug development consulting
• Therapeutic asset development
• Biotech company formation

Headquarters

HQ city

Jersey City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Venture Capital Returns: As a venture creation firm, ATP Ventures Partner generates returns through equity ownership in co-founded biotech companies, guiding ventures toward successful exits including IPOs and M&As.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

ATP Ventures Partner is a biotech venture creation firm that scouts global therapeutic assets and co-founds drug development companies with entrepreneurs and scientists. The firm partners with world-renowned research institutions including Cornell, NYU, Harvard, and UPenn to identify high-potential assets, advance drug candidates through clinical stages, and guide portfolio ventures toward successful exits such as IPOs and M&As. Following the October 2024 acquisition of Tupelo Brittany, ATP also offers biotech consulting services covering fundraising, business development, in-licensing/out-licensing, deal-making, market insight, and financial strategy.

Product overview

ATP Ventures Partner is a biotech venture creation firm that creates and invests in drug development companies. The firm operates through hands-on venture creation and co-founding with entrepreneurs, offering expertise in advancing drug candidates through clinical stages. The core offering is therapeutic asset development and company creation, with a focus on supporting early-stage ventures and scientists. Portfolio companies include Flatbird Therapeutics (focused on women's health) and the acquired Tupelo Brittany consulting practice.

Differentiator

Problem solved

Functional benefit

Products and services

• Venture Creation and Co-Founding Services End-to-end biotech venture creation services for entrepreneurs and scientists, including global therapeutic asset scouting, co-founding of drug development companies, clinical development guidance, fundraising support, strategic partnership facilitation, and exit planning (IPOs and M&As). For early-stage biotech founders and academic scientists developing therapies for life-threatening diseases.
• Biotech Consulting and Advisory Services (Tupelo Brittany) Strategic advisory services for pharmaceutical and biotechnology clients, including fundraising support, business development, in-licensing and out-licensing, deal-making strategies, market insight, business intelligence, and market development. Acquired via the Tupelo Brittany acquisition and now integrated into ATP Ventures Partner's offerings.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Partnerships

Six partnerships are on record, tiered core.

• Tupelo BrittanycoreStrategic or Co-development Partner · 8 October 2024Acquisition of Tupelo Brittany, a leading biotech consulting firm, enhances ATP Ventures Partner's capabilities in integrated company creation, business development, in-out licensing, deal-making, and financial strategies. The combined entity strengthens hands-on role in company formation and therapeutic asset development.
• Cornell UniversitycoreStrategic or Co-development PartnerPartnering with Cornell for venture creation, leveraging world-renowned research capabilities in therapeutic development.
• NYU (New York University)coreStrategic or Co-development PartnerStrategic partnership with NYU for co-creating biotech ventures, utilizing research expertise and academic resources.
• Harvard UniversitycoreStrategic or Co-development PartnerCollaboration with Harvard for venture creation, tapping into elite research and innovation ecosystem.
• UPenn (University of Pennsylvania)coreStrategic or Co-development PartnerPartnership with UPenn for co-founding biotech ventures, leveraging cutting-edge research capabilities.
• Flatbird TherapeuticscoreStrategic or Co-development PartnerPortfolio company focused on women's health innovation. Founded with vision and led by an innovative female team, Flatbird Therapeutics stands at the forefront of biotech innovation.

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Direct peers

• Apple Tree Partners: Biotech venture creation and early-stage investment firm that partners with entrepreneurs to build therapeutic companies. Comparable in company-creation focus and therapeutic breadth.
• Frazier Life Sciences: Biotechnology-focused venture firm investing in and helping build therapeutic companies across multiple indications. Comparable to ATP in therapeutic breadth and early-stage company-building focus.
• Third Rock Ventures: Venture creation firm focused on launching and building biotech companies from academic and institutional science. Strongly comparable to ATP in the co-founding, asset-scout, multi-therapeutic-area approach.
• Atlas Venture: Early-stage biotech-focused venture firm that builds companies from inception through company-creation activities. Directly comparable to ATP in stage, therapeutic breadth, and hands-on company formation model.
• RA Capital Management: Healthcare-focused investment firm with deep biotech portfolio and hands-on company involvement. Comparable to ATP in life-sciences focus and ability to support companies through clinical milestones.
• Flagship Pioneering: Pioneer of biotech venture creation, originating and co-founding companies around platform technologies. Closely comparable to ATP's model of scouting therapeutic assets and co-founding with entrepreneurs across multiple therapeutic areas.
• OrbiMed: Healthcare-dedicated investment firm spanning venture, growth, and credit across biopharma. Comparable to ATP in biotech investment focus and ability to underwrite therapeutic development across stages.
• ARCH Venture Partners: Long-standing biotech-focused venture firm that invests in and helps build transformative life-science companies. Comparable in academic sourcing and long-horizon therapeutic company building.
• 5AM Ventures: Early-stage biotech venture firm investing across platforms, small molecules, and therapeutics. Comparable to ATP in stage, therapeutic focus, and academic/early-stage orientation.
• Versant Ventures: Healthcare-focused venture firm that creates and invests in biotech companies across multiple therapeutic areas. Comparable in stage, therapeutic breadth, and company-creation approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/atp-ventures

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ATP Ventures Partner